Straits Times Index
3,280.10 -7.65 (-0.23%) Nikkei
37,934.76 +306.28 (+0.81%) Hang Seng
17,651.15 +366.61 (+2.12%) FTSE 100
8,139.83 +60.97 (+0.75%) Bitcoin USD
63,605.12 +464.93 (+0.74%) CMC Crypto 200
1,393.08 -3.45 (-0.25%)
AlloVir, Inc. (ALVR)
After hours:
| Previous close | 0.8000 |
| Open | 0.7801 |
| Bid | 0.7941 x 100 |
| Ask | 0.8000 x 200 |
| Day's range | 0.7701 - 0.8047 |
| 52-week range | 0.6230 - 6.1200 |
| Volume | |
| Avg. volume | 659,184 |
| Market cap | 91.597M |
| Beta (5Y monthly) | 0.85 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
AlloVir Provides Updates on Phase 3 Clinical Development Program for Posoleucel, an Allogeneic Virus-Specific T Cell Therapy
Company to discontinue its three Phase 3 posoleucel studies following separate, pre-planned DSMB futility analyses concluding the studies were unlikely to meet their primary endpoints; no safety concerns identified Company to prioritize capital preservation and review strategic options AlloVir reported $213.3 million in cash, cash equivalents, and short-term investments as of September 30, 2023 WALTHAM, Mass., Dec. 22, 2023 (GLOBE NEWSWIRE) -- AlloVir, Inc. (Nasdaq: ALVR), an allogeneic T cell i
- Business Wire
AlloVir to Present at the Piper Sandler 35th Annual Healthcare Conference
WALTHAM, Mass., November 16, 2023--AlloVir, Inc. (Nasdaq: ALVR), a late-clinical stage allogeneic T cell immunotherapy company, today announced that Diana Brainard, M.D., Chief Executive Officer, will participate in a fireside chat at the Piper Sandler 35th Annual Healthcare Conference in New York City, NY on Tuesday, November 28, 2023 at 10:00 a.m. ET.
- Business Wire
AlloVir Reports Third Quarter 2023 Financial Results
WALTHAM, Mass., November 02, 2023--AlloVir, Inc. (Nasdaq: ALVR), a late-clinical stage allogeneic T cell immunotherapy company, today reported financial results from the third quarter ended September 30, 2023. AlloVir continues to progress its highly innovative lead therapeutic candidate, posoleucel, by enrolling globally in three Phase 3 trials for first-to-market indications. AlloVir is in a position of strength with significant financial resources to support operations through topline data re
